EGFR and neoplasm: Muscarinic receptors are expressed in MDA-MB-231 tumor cells and cell viability is reduced when carbachol or arecaidine propargyl ester, a nonselective or selective mAChR M2 agonist, is combined with paclitaxel, resulting in downregulation of EGFR and other transporters; and those combined drugs inhibit tumor cell migration and have antiangiogenic effects in vitro and in vivo (in immune depressed mice), providing compelling evidence for using mAChR M2 as therapeutic targets for triple-negative cancers [62].